Every trade that managers of Hanger, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The past year has been quiet: not a single insider filing for Hanger, Inc. The previous disclosure was published on 4 October 2022.
Looking back to 2021, when coverage begins, insiders filed no purchases and 6 sales.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended December 2021 · cache
25 of 92 declarations
Hanger, Inc. (ticker HGR) is a U.S.-listed company traded in the United States on the NYSE/NASDAQ, operating in the orthotic and prosthetic (O&P) care market. Its core business is to design, fabricate, distribute, and deliver medical solutions for patients dealing with limb loss, limb difference, and other mobility-related or orthopedic support needs. The company is best known for Hanger Clinic, its patient-care network, and for an integrated O&P ecosystem that connects clinical care, product development, fabrication, distribution, and patient support. ([news.hanger.com](https://news.hanger.com/about-us/?utm_source=openai))
Hanger traces its origins back to 1861, when James Edward Hanger founded the business after losing a leg during the American Civil War and developing an early prosthetic solution. That origin gives the company a uniquely long history in the mobility-care field. Over time, Hanger evolved from an artisanal prosthetics business into a scaled clinical and manufacturing platform. The company is headquartered in Austin, Texas, reinforcing its base in the United States and its access to healthcare and technology talent. ([news.hanger.com](https://news.hanger.com/about-us/?utm_source=openai))
Operationally, Hanger is organized into two main segments: Patient Care and Products & Services. Patient Care includes the Hanger Clinic network, which provides individualized orthotic and prosthetic treatment and custom patient solutions. Products & Services covers manufacturing and distribution of O&P components, orthoses, prostheses, pediatric solutions, and related devices. Management emphasizes an outcomes-based model, meaning the company focuses on measurable clinical results, functional improvement, and long-term patient value rather than simply product volume. ([news.hanger.com](https://news.hanger.com/about-us/?utm_source=openai))
From a competitive standpoint, Hanger is one of the better-known scale players in the U.S. O&P market. Its strengths include national reach, an integrated care-and-products model, and continued investment in clinical research and education. The company also highlights its professional training infrastructure, including a national O&P residency program that has trained more than 950 residents since 1996, as well as an institute dedicated to research and evidence-based care. ([corporate.hanger.com](https://corporate.hanger.com/news/2026/hanger-institute-for-clinical-research-and-education-releases-2025-2026-annual-report-highlighting-landmark-advances-in-orthotic-and-prosthetic-care/?utm_source=openai))
Geographically, Hanger’s footprint is overwhelmingly domestic, with more than 925 patient-care locations across the country according to recent company communications, plus U.S.-based manufacturing and distribution operations. A notable operational development was the 2024 opening of a West Coast distribution center in Fresno, California, which supports nationwide fulfillment for O&P products. ([corporate.hanger.com](https://corporate.hanger.com/news/2025/hanger-clinic-enters-clinical-services-agreement-for-orthotic-and-prosthetic-care-with-premier-inc/?utm_source=openai))
Recent strategic and product news underscores the company’s innovation focus. In 2025, Hanger announced an impending acquisition of Point Designs, a firm specializing in partial-hand prosthetics and additive manufacturing. The company’s portfolio also saw new product activity through Surestep’s 3D-printed cranial remolding orthosis launch. In 2026, Hanger Institute released its 2025–2026 annual report, highlighting progress in clinical research, AI-supported decision-making, and evidence-based O&P care. Taken together, these developments point to a company positioning itself as a clinically differentiated leader in a specialized healthcare niche. ([news.hanger.com](https://news.hanger.com/press-releases/press-release-details/2025/Hanger-Announces-Impending-Acquisition-of-Point-Designs/default.aspx?utm_source=openai))
Purchases our model currently ranks for the recommendations list.
All recommendations| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2021 | 1.12 bn USD | 42.0 m USD | 1.07 USD | 10-K |
| Dec 2020 | 1.00 bn USD | 38.2 m USD | 0.99 USD | 10-K |
| Dec 2019 | 1.10 bn USD | 27.5 m USD | 0.72 USD | 10-K |
| Dec 2018 | 1.05 bn USD | -858,000 USD | -0.02 USD | 10-K |
| Dec 2017 | 1.04 bn USD | -104.7 m USD | -2.89 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.